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Background. Bedaquiline has a black-box warning of the risk of arrhythmias and sudden death. This study aimed to determine 
the incidence of QTc prolongation and cardiac events in patients receiving bedaquiline for drug-resistant tuberculosis (DR-TB) 
under programmatic conditions.
Methods. Retrospective cohort study of patients receiving bedaquiline at a DR-TB hospital in KwaZulu Natal, South Africa from 
September 2017 to February 2019. The primary outcome, a prolonged QT interval corrected using the Fridericia formula (QTcF), 
was defined as QTcF >500 ms, QTcF change >60 ms from baseline, or both.
Results. Among 420 patients (66.2% male, median age 36 years), the median QTcF was 406.4 (interquartile range [IQR], 389.1–
421.3) ms at baseline, increasing to 430.5 (IQR, 414.4–445.1) ms by 3 months and 434.0 (IQR, 419.0–447.9) ms at 6 months. Eighteen 
of 420 patients (4.3%) had a QTcF >500 ms and 110 of 420 patients (26.2%) had a QTcF change >60 ms. There were no recorded ar-
rhythmias or cardiac deaths. Odds of prolonged QTcF were increased with concomitant azoles (adjusted odds ratio [aOR], 5.61 [95% 
confidence interval (CI), 2.26–13.91]; P < .001) and an inverse association with HIV-positive status (aOR, 0.34 [95% CI, .15–.75]; P 
= .008) and hypertension (aOR, 0.13 [95% CI, .02–.86]; P = .02). After prolongation, the QTcF declined to <500 ms, whether drugs 
were interrupted or not.
Conclusions. We observed a modest prolongation of QTcF, maximal at week 15; there were no recorded arrhythmias or related 
deaths.
Keywords.  bedaquiline; QT interval prolongation; tuberculosis.
There were an estimated 465  000 incident cases of drug-
resistant tuberculosis (DR-TB) in 2019, 14 000 of which were in 
South Africa [1]. Treatment for DR-TB has long relied on pro-
longed regimens of poorly efficacious, toxic drugs, with treat-
ment success at around 50% globally [2, 3]. The advent of novel 
drugs such as bedaquiline, delamanid, and pretomanid and re-
purposing of drugs such as clofazimine and linezolid promise 
improved DR-TB treatment.
Bedaquiline belongs to a novel class of TB drugs, the 
diarylquinolines, and is associated with improved outcomes 
[4–6]. World Health Organization (WHO) DR-TB guidelines 
categorize bedaquiline as a group A drug to be included as part 
of all long regimens for DR-TB [7]. In South Africa, bedaquiline 
is used as part of a modified 9- to 12-month regimen [8]. As 
of June 2020, 29 193 patients in South Africa have received 
bedaquiline as part of their DR-TB therapy [9]. Bedaquiline 
has a favorable safety profile [10], but is known to prolong the 
QT interval on electrocardiogram (ECG). QT prolongation in-
creases the risk of arrhythmias, specifically torsades de pointes 
[11]. In the phase 2b trial of bedaquiline (TMC207-C208), 
there was an excess of deaths in the bedaquiline arm (10/79 
[13%]) compared to the placebo arm (2/81 [2%]) (P = .02 for 
difference) [12]. Although no association was found between 
these deaths and QT prolongation and most deaths occurred 
after bedaquiline had been completed [5], the United States 
Food and Drug Administration issued a black-box warning of 
a risk of QT prolongation, arrhythmias, and sudden death with 
bedaquiline [13, 14].
In subsequent trials (TMC207-C209) and programmatic 
evaluations, QT prolongation with bedaquiline has been con-
firmed [11, 15, 16]. However, the QT interval infrequently 
exceeded 500  ms, arrhythmias were rarely reported, and no 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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episodes of torsades de pointes have been reported [5, 11]. 
There is a need for further data on the safety of bedaquiline in 
South Africa where it is used alongside clofazimine, a fluoro-
quinolone (typically levofloxacin), and often other drugs (eg, 
azoles), which also prolong the QT interval. The South African 
bedaquiline clinical access program, where bedaquiline was 
used in combination with clofazimine and fluoroquinolones 
in the majority of patients, reported low rates of QT prolon-
gation. However, many of these patients had a “baseline” ECG 
performed while already taking moxifloxacin, making QT pro-
longation due to bedaquiline difficult to identify [2, 16, 17].
South African guidelines recommend performing an ECG 
at baseline, after 2 weeks, 4 weeks then monthly while on 
bedaquiline, or more frequently if additional QT-prolonging 
drugs are being taken [8]. If the QT interval corrected using the 
Fridericia formula (QTcF) is >470 ms but <500 ms, asympto-
matic patients can be monitored with serial ECGs weekly until 
stable. If QTcF is >500 ms, all QT-prolonging drugs are to be 
stopped, followed by management of other causes of QTc pro-
longation, and 48 hours later, a repeat ECG is recommended 
[8]. Each clinic delivering DR-TB treatment requires an ECG 
machine and expertise to read the ECG. This is not always 
available at peripheral centers, imposes additional expense, 
and may act as a barrier to bedaquiline rollout in some settings 
[18]. Understanding the timing of QT prolongation and who is 
most at risk may help guide ECG monitoring requirements in 
South Africa.
We report the incidence of QTc prolongation and cardiac 
events for a large cohort of patients treated with a combination 




This was a retrospective cohort study at a specialist DR-TB 
hospital in eThekwini District, KwaZulu-Natal, South Africa. 
Consecutive patients initiating bedaquiline-based DR-TB 
therapy from September 2017 (the date from which bedaquiline 
was first available in the hospital) to February 2019 were iden-
tified using both the hospital register and the Electronic Drug-
Resistant Tuberculosis Register (EDRWeb). The standard 
duration of bedaquiline therapy as per South African guidelines 
was 6 months [8].
Inclusion and Exclusion Criteria
Patients were excluded if they were not treated with a 
bedaquiline-based DR-TB regimen, if they did not have a base-
line ECG recorded within the 4 weeks prior to bedaquiline in-
itiation, or if they did not have at least 1 follow-up ECG in the 
6  months of bedaquiline treatment. Patients were eligible re-
gardless of their background DR-TB regimen.
Data Collection
A standardized data collection tool was developed using 
Open Data Kit [19]. We collected relevant baseline char-
acteristics, including comorbidities, and follow-up data 
for the duration of bedaquiline therapy, including all other 
antituberculosis drugs and any interruptions in therapy. 
Electrolytes were measured, but not in a consistent manner, 
limiting analysis for other risk factors of torsades de pointes. 
Twelve-lead ECGs were reviewed by a clinician and heart 
rate, QT interval, and any abnormalities were recorded. The 
QT interval was corrected for heart rate using the Fridericia 
formula: QTcF = QT/ 3
√
RR . Significant QT interval prolon-
gation was defined, in accordance with WHO guidelines [7], 
as a QTcF measurement >500 ms, or an increase of >60 ms 
from baseline.
Statistical Analysis
We used Kaplan-Meier methods to estimate retention on 
bedaquiline treatment for 6  months. Person-time was calcu-
lated from the start of bedaquiline therapy until the earliest of 
stopping bedaquiline (either permanently or an interruption of 
treatment), death, loss to follow-up, or 183 days on treatment. 
Patients were censored when transferred out. Patients who were 
prescribed bedaquiline for <6 months were censored on the date 
of completion of therapy. Those who were still on treatment at 
the time of record review were administratively censored on 
the date of their last record. As a sensitivity analysis, patients 
who interrupted treatment temporarily were considered to be 
retained on treatment, and person-time was calculated ignoring 
the interruption.
We used random effects logistic regression to estimate odds 
ratios (ORs) and 95% confidence intervals (CIs) for the associ-
ation of factors with the primary outcome of QTcF >500 ms or 
an increase of >60 ms from baseline at each visit. We restricted 
the analysis to the first 26 weeks of treatment with bedaquiline. 
We examined the change in QTcF over time using mixed-effects 
linear regression to account for the correlation of observations 
within patients. To allow for nonlinear effects of time, visit week 
was modeled using restricted cubic splines with 4 knots; this 
approach provides a flexible way to model the shape of the re-
lationship of a continuous covariate with the outcome. We ad-
justed for age, sex, and visit week as a priori confounders; visit 
week was modeled using restricted cubic splines. Factors that 
were associated with the outcome at P < .20 after adjusting for 
age, sex, and week were included in a multivariable model; those 
that remained associated at P < .10 were retained. All analyses 
used Stata version 15 software.
Patient Consent Statement
The study was approved by the research ethics committees of 
the University of KwaZulu-Natal (BE314/19) and the London 
School of Hygiene and Tropical Medicine (16481), and by the 
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Department of Health of KwaZulu-Natal (KZ_201906_001). 
Due to the retrospective nature of this study, the requirement 
for written informed consent was waived.
RESULTS
Patient Enrollment
Among 450 patient records reviewed, 420 were eligible for in-
clusion. Reasons for exclusion were as follows: no ECG before 
bedaquiline treatment initiation (n = 23), no baseline ECG 
within 4 weeks of bedaquiline treatment initiation (n = 6), or 
no post–bedaquiline initiation ECG (n = 1).
Baseline Characteristics
Among 420 patients, the median age was 36 (interquartile range 
[IQR], 29–44) years and 66.2% were male (Table 1). The ma-
jority (312/420 [74.3%]) were human immunodeficiency virus 
(HIV) positive, and 201 of 312 (64.4%) were taking antire-
troviral therapy (ART) prior to starting bedaquiline. Median 
CD4 count at time of bedaquiline initiation was 241 cells/
mm3. All 420 patients were prescribed bedaquiline with an op-
timized background regimen that included clofazimine and 
levofloxacin. Forty-seven of 420 (11.2%) were on moxifloxacin 
at the time of baseline ECG measurement; 46 of these were sub-
sequently converted to levofloxacin.
Duration of Bedaquiline Treatment
Median time on bedaquiline among the 420 patients was 6.0 
(IQR, 5.0–6.0) months. The Kaplan-Meier estimate for reten-
tion on bedaquiline treatment at 6  months, not discounting 
treatment interruptions, was 84.5% (Figure 1). At completion of 
the data collection period, 23 (5.5%) patients were still under-
going bedaquiline treatment, and 27 (6.4%) patients had trans-
ferred to another hospital before the end of treatment. Of the 62 
(14.8%) patients who were not retained on bedaquiline treat-
ment, 17 of 62 (27.4% [4.0% of all patients]) were lost to fol-
low-up, 12 (19.4% [or 2.9% of all patients]) died, and 7 (11.3% 
[1.7% of all patients]) stopped treatment. Twenty-six of 62 pa-
tients (41.9% [6.2% of all patients]) temporarily interrupted 
treatment; median time to restart bedaquiline was 28 (IQR, 
15–54) days. In the sensitivity analysis discounting treatment 
interruptions, 90.4% of patients were retained on bedaquiline 
treatment at 6 months.
Concomitant Medication
Two hundred one of 312 (64.4%) patients living with HIV 
were already on ART prior to DR-TB therapy: this increased 
to 99% (309/312) during bedaquiline DR-TB therapy treat-
ment. Median time to ART initiation was 24 (IQR, 17–34) 
days after bedaquiline treatment initiation. All ART regimens 
included 2 nonnucleoside/nucleotide reverse transcriptase in-
hibitors; the third agent was nevirapine in 208 of 309 (67.3%), 
lopinavir/ritonavir in 103 (33.3%), atazanavir/ritonavir in 2, 
and raltegravir and dolutegravir in 1 each.
QTc Interval Measures and Clinical Events
The median QTcF interval at baseline was 406.4 (IQR, 
389.1–421.3) ms. Eighteen patients (4.3%) had a recorded 
QTcF >450  ms at baseline, of whom 6 (33%) had a repeat 
baseline ECG; QTcF remained >450  ms in all cases. Two pa-
tients (11%) had a QTcF >500  ms at baseline, both of whom 
commenced therapy without a repeat predose ECG. A median 
of 8 ECGs (IQR, 7–9) per patient were performed during the 
6 months after starting bedaquiline. During these 6 months, 18 
patients (4.3%) experienced at least 1 episode of QTcF >500 ms 
(24 episodes), and 110 patients (26.2%) had a change of >60 ms 
from baseline (253 episodes). Only 2 of these patients were 
among the 18 patients with QTcF >450 ms at baseline (11%), 
compared to 27% of patients with baseline QTcF <450  ms 
(P = .13).
When modeled as a function of time, the largest increase 
in QTc occurred in the first 6 weeks after bedaquiline initia-
tion, after which the rate of increase leveled off (Figure 2). After 
Table 1. Demographic and Clinical Characteristics of 420 Patients at 
Baseline
Characteristic No. (%) or Median (IQR)
Age, y, median (IQR) 36 (29–45)
Sex, male 278 (66.2)
Non-smoker 261 (62.4)
HIV status
 Positive 312 (74.3)
 On ART before DR-TB treatment 201 (64.4)
 CD4 count, cells/mm3, median (IQR) (n = 309) 175 (65–376)
Hypertension (yes) 32 (7.6)
Diabetes (yes) 19 (4.5)
Hypothyroidism
 Yes 95 (22.6)
 Unknown 325 (77.4)
Epilepsy (yes) 6 (1.4)
QTcF at baseline, ms
 >450 15 (3.6)
 >500 2 (0.5)
QTcF at baseline, ms, median (IQR) 406.4 (389.1–421.3)
Optimized background DR-TB regimen  
 Including clofazimine 419 (99.8)
 Including levofloxacin 419 (99.8)
Third agent in optimized ART regimen
 Nevirapine 208/309 (67.3)
 Lopinavir/ritonavir 103/309 (33.3)
 Atazanavir/ritonavir 2/309 (0.6)
 Raltegravir 1/309 (0.3)
 Dolutegravir 1/309 (0.3)
Abbreviations: ART, antiretroviral therapy; DR-TB, drug-resistant tuberculosis; HIV, human 
immunodeficiency virus; IQR, interquartile range; QTcF, Fridericia-corrected QT interval.
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3 months on bedaquiline therapy, median QTc was 430.5 (IQR, 
414.4–445.1) ms and after 6 months it was 434.0 (IQR, 419.0–
447.9) ms (Figure 3). Median change in QTcF from baseline 
after 3 months on bedaquiline therapy was 24.5 (IQR, 6.2–43.4) 
ms and after 6 months it was 29.5 (IQR, 9.6–47.2) ms (Figure 
4). Sixty-five patients (15.5%) were on treatment with an azole 
at the time of ECG measurement (202 visits). There were 42 
occurrences in 14 patients of QTcF change >60 ms while taking 
concomitant azoles, among which there were 5 occurrences in 
1 patient of QTcF >500 ms.
There were no clinically significant cardiovascular events 
or arrhythmias recorded. Twelve patients (2.7%) died, none 
of whom had a recorded QTcF >500 ms and all of whom had 
ECGs performed at timepoints consistent with the guidance. 
The cause of death was not recorded in the medical records.
Management of QTc >500 ms and QTcF Change >60 ms
No action was taken if there was a QTcF change >60 ms above 
baseline (253 episodes). The 24 episodes of QTcF >500 ms are 
outlined in Table 2; the QT interval declined after prolongation 
without clinical sequelae, whether bedaquiline, levofloxacin, or 
clofazimine were interrupted or not. QTcF returned to <500 ms 
in all cases irrespective of management. There were too few data 
for formal analysis.
Predictors of QTcF Prolongation
We recorded 254 episodes of QTcF >500  ms or change from 
baseline >60  ms among 111 patients during the 6  months of 
bedaquiline therapy. The odds of this combined outcome of 
QTcF prolongation increased over time and were highest after 



















0 2 4 6 8 10 12 14 16 18 20 22 24 26
Weeks since bedaquiline initiation
Figure 2. Mean increase in Fridericia-corrected QT interval (QTcF) from baseline over time, modeled using restricted cubic splines with 4 knots in a mixed-effect linear 
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Figure 1. Kaplan-Meier survival estimate of remaining on bedaquiline treatment at 6 months. Vertical marks show censoring times.
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there was strong evidence of an increased odds of QT pro-
longation with concomitant azole antifungals (adjusted OR 
[aOR], 5.61 [95% CI, 2.26–13.91]; P < .001); median time on 
azoles was 14 (IQR, 14–14) days and there was strong evidence 
of an inverse association with HIV-positive status (aOR, 0.34 
[95% CI, .15–.75]; P = .008) and hypertension (aOR, 0.13 
[95% CI, .02–.86]; P = .02) (Table 3). There was also weak evi-
dence of an inverse association with diabetes (aOR, 0.11 [95% 
CI, .01–1.31]; P = .11). There was no evidence of an association 
with QTc prolongation in 12 of 420 (2.9%) patients treated con-
comitantly with bedaquiline and delamanid (aOR, 1.17 [95% 
CI, .30–4.58]; P = .82).
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Figure 3. Box and whisker plots of Fridericia-corrected QT interval (QTcF) values over time, during the 6 months after bedaquiline initiation. The vertical line within the box 
indicates the median, the boundaries of the box indicate the interquartile range (25th and 75th percentiles), and the whiskers indicate values that are within 1.5 times the 
interquartile range above the 75th percentile, or 1.5 times the interquartile range below the 25th percentile. Values outside that range are plotted as individual points. The 
number of electrocardiograms at each timepoint are indicated in italics below the x-axis.
Weeks since bedaquiline initiation
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Figure 4. Box and whisker plots of change in Fridericia-corrected QT interval (QTcF) from baseline over time, during the 6 months after bedaquiline initiation. The vertical 
line within the box indicates the median, the boundaries of the box indicate the interquartile range (25th and 75th percentiles), and the whiskers indicate values that are 
within 1.5 times the interquartile range above the 75th percentile, or 1.5 times the interquartile range below the 25th percentile. Values outside that range are plotted as 
individual points. The number of electrocardiograms at each timepoint are indicated in italics below the x-axis.
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DISCUSSION
This study among patients taking bedaquiline under program-
matic conditions demonstrated a progressive increase in QTcF 
from baseline, with a cumulative incidence of QTcF >500  ms 
or QTcF >60 ms from baseline of 4.3% and 26.2%, respectively, 
over 6 months of bedaquiline therapy, and maximum odds for 
the combined outcome at 15 weeks of bedaquiline therapy. 
However, we found no evidence of clinical adverse events asso-
ciated with these changes.
Under randomized controlled trial conditions and in com-
bination with ofloxacin or levofloxacin, but without concom-
itant clofazimine, the mean increase in QTc is in the order of 
11.9–15 ms, with an incidence of QTcF >500 ms of ≤1% [10, 12, 
20]. However, several other observational studies have reported 
a higher average increase in QTcF (31.9 ms median maximum 
increase [21] and 49 ms mean change from baseline [21]) and 
a higher incidence of QTcF >500 ms (11% [21] and 15% [22], 
respectively). There are several potential explanations for the 
higher incidence of QT prolongation seen in our study and other 
observational cohorts. Clofazimine monotherapy increases the 
QT interval and in the original open-label trial of bedaquiline 
(C209), the mean increase in QTcF at week 24 was far higher 
in participants taking vs not taking clofazimine (31.9  ms vs 
12.3 ms) [15, 23]. Several other cohorts have included patients 
taking concomitant clofazimine, but to our knowledge this is 
the largest study reporting QT prolongation in a cohort where 
concomitant clofazimine administration was universal. The 
largest comparable study in South Africa among 200 patients 
receiving bedaquiline, clofazimine, and fluoroquinolones re-
ported a median increase in QTc of 11 (IQR, -6 to 27) ms and 
5 cases of QTcF >500  ms, but many patients were already on 
moxifloxacin when “baseline” ECG monitoring was performed, 
making the results difficult to interpret [2, 16, 17]. Participants 
in the bedaquiline licensing trials were excluded if they had a 
QTcF >450 ms at baseline or were taking other drugs likely to 
prolong the QT interval or to lead to drug–drug interactions 
(including antiretrovirals) [12, 15]. Our study was designed 
to represent patients being treated for DR-TB under pro-
grammatic conditions and included >90% of patients started 
on bedaquiline in this facility during the study time period. 
Many were taking antiretroviral and other concomitant drugs. 
Of note, 18 patients (4.3%) were initiated on bedaquiline with 
a baseline QTcF >450  ms, and 2 patients (0.5%) with a base-
line QTcF >500 ms. It is therefore probable that patients in our 
study, like others in DR-TB programs, had higher baseline risk 
for QT prolongation than those recruited in clinical trials. It was 
reassuring that we found no evidence of clinical consequences 
of QT prolongation, consistent with a growing body of literature 
suggesting that arrhythmias and sudden cardiac death are rare 
among people taking bedaquiline under routine conditions [6, 
11, 16]. QT measurements are known to vary by up to 100 ms 
within an individual patient in a single day and this variability 
is influenced by factors such as patient positioning, time since 
last meal, and time of the day [24, 25]. ECG monitoring in clin-
ical trials typically follows a strict protocol to reduce variability. 
ECG monitoring in a “real world” setting may overestimate 
the incidence of episodes of QT prolongation based on single 
ECGs. We argue that it is important to establish the incidence of 
QT prolongation identified using routine monitoring, as this is 
what programmatic clinical decisions will be based on.
There are a number of established risk factors that predis-
pose to QTc prolongation, notably female sex, age, electrolyte 
disturbance, and certain drug classes [26]. In our study, azole 
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Figure 5. Association of Fridericia-corrected QT interval (QTcF) prolongation (QTcF >500 ms or change from baseline >60 ms) with time since bedaquiline start, modeled 
using restricted cubic splines with 4 knots in a random-effect logistic regression model. Solid line is estimated odds ratio (OR) for QTcF prolongation; dashed lines are 95% 
confidence intervals. Week 2 was used as the reference to calculate the ORs. 
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only 1 patient had a documented QTcF >500  ms. We found 
no evidence of an association with QTc prolongation and 
delamanid coadministration, but this was limited to observation 
of 12 patients. Ninety-nine percent of the HIV-positive patients 
in our cohort received ART. Surprisingly, being HIV positive 
was inversely associated with QTc prolongation, but there may 
Table 3. Factors Associated With Combined Outcome of Fridericia-Corrected QT Interval >500 ms and/or Change From Baseline >60 ms at Each Visit, 
During 6 Months After Bedaquiline Initiation
Characteristic
Patients With QTcF >500 ms or 
Change >60 ms/Total Patients (%) 
(N = 420 Patients)
ECGs With QTcF >500 ms or 
Change >60 ms/Total ECGs (%)  
(n = 2955 ECGs)
Crude OR (95% 
CI)
Adjusted OR (95% 
CI)a
Age group, y   P = .83 P = .15
 <30 27/119 (22.7) 65/781 (8.3) 1 1
 30–49 69/247 (27.9) 160/1769 (9.0) 1.23 (.60–2.53) 1.91 (.85–4.29) 
 ≥50 15/54 (27.8) 29/405 (7.2) 1.03 (.36–2.93) 2.90 (.85–9.91) 
Sex   P > .99 P = .36 
 Male 75/278 (27.0) 169/1982 (8.5) 1 1
 Female 36/142 (25.4) 85/973 (8.7) 1.00 (.52–1.92) 1.40 (.68–2.88) 
HIV positive   P = .18 P = .008 
 No 36/110 (32.7) 75/788 (9.5) 1 1
 Yes 75/310 (24.2) 179/2167 (8.3) 0.63 (.32–1.24) 0.34 (.15–.75) 
Hypertension   P = .02 P = .02 
 No 108/388 (27.8) 249/2743 (9.1) 1 1
 Yes 3/32 (9.4) 5/212 (2.4) 0.14 (.03–.73) 0.13 (.02–.86) 
Diabetes   P = .05 P = .06 
 No 109/401 (27.2) 252/2823 (8.9) 1 1
 Yes 2/19 (10.5) 2/132 (1.5) 0.12 (.01–1.03) 0.11 (.01–1.31) 
Levofloxacinb   P = .06 P = .37 
 No 1/1 (100) 22/133 (16.5) 1 1
 Yes 110/419 (26.3) 232/2822 (8.2) 0.48 (.23–1.04) 0.68 (.29–1.58) 
Clofazamineb   P = .07 P = .59 
 No 1/2 (50.0) 25/123 (20.3) 1 1
 Yes 110/418 (26.3) 229/2832 (8.1) 0.51 (.25–1.06) 0.80 (.36–1.77) 
Moxifloxacinb   P = .72 P = .44 
 No 110/413 (26.6) 253/2924 (8.7) 1 1
 Yes 1/7 (14.3) 1/31 (3.2) 0.54 (.02–15.44) 0.25 (.01–10.82) 
Delamanidb   P = .26 P = .82 
 No 107/408 (26.2) 246/2889 (8.5) 1 1
 Yes 4/12 (33.3) 8/66 (12.1) 2.08 (.59–7.35) 1.17 (.30–4.58) 
Lopinavir/
ritonavirb
  P = .96 P = .53 
 No 83/320 (25.9) 200/2343 (8.5) 1 1
 Yes 28/100 (28.0) 54/612 (8.8) 1.02 (.51–2.01) 0.79 (.37–1.68) 
Metoclopramideb   P = .02 P = .42 
 No 95/353 (26.9) 250/2832 (8.8) 1 1
 Yes 16/67 (23.9) 4/123 (3.3) 0.23 (.07–.80) 0.59 (.16–2.22) 
Amitriptyline   P = .84 P = .96 
 No 110/416 (26.4) 253/2946 (8.6) 1 1
 Yes 1/4 (25.0) 1/9 (11.1) 0.63 (.01–48.05) 0.89 (.01–156.80) 
Haloperidolb   P = .57 P = .69 
 No 110/411 (26.8) 253/2944 (8.6) 1 1
 Yes 1/9 (11.1) 1/11 (9.1) 2.17 (.15–31.94) 1.79 (.10–31.32) 
Cotrimoxazoleb   P = .99 P = .37 
 No 38/120 (31.7) 78/943 (8.3) 1 1
 Yes 73/300 (24.3) 176/2012 (8.7) 1.00 (.54–1.83) 1.75 (.51–6.06) 
Azole 
antifungalsb
  P = .01 P < .001
 No 89/355 (25.1) 212/2753 (7.7) 1 1
 Yes 22/65 (33.8) 42/202 (20.8) 2.82 (1.26–6.30) 5.61 (2.26–13.91)
Abbreviations: CI, confidence interval; ECG, electrocardiogram; HIV, human immunodeficiency virus; OR, odds ratio; QTcF, Fridericia-corrected QT interval. 
aAdjusted for age, sex, and visit week (a priori), HIV status, hypertension, diabetes, and azole antifungals. 
bTaking the medication concomitant with bedaquiline at the time of the ECG measurement.
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be residual confounding. The interim analysis of 91 patients in 
the bedaquiline clinical access program cohort found no asso-
ciation with QTcF prolongation and positive HIV status [16]. 
Increased incidence of QT prolongation has been described 
among HIV-positive people receiving efavirenz [26, 27]; in 
line with national guidelines, no patients in our cohort were 
taking efavirenz [8, 26]. The data are reassuring for the use of 
bedaquiline among patients taking ART.
In our study, in line with guidelines [8], we observed no change 
in management if QTcF increased by 60  ms. Management in 
response to patients with QTcF >500 ms varied based on phy-
sician discretion, as shown in Table 2. The rationale was not 
clearly documented in medical records, a limitation of this ret-
rospective study. In all patients, the QTc reverted to <500 ms 
irrespective of whether or not drugs were stopped. Drug inter-
ruption introduces the risk of poor outcomes and resistance 
development [28, 29]. The optimal management of QTc prolon-
gation during bedaquiline therapy is yet to be defined.
In this cohort the QTcF increased most steeply from baseline 
in the first 4–6 weeks, then continued to increase more slowly 
until the end of bedaquiline therapy. Similarly, in the C208 li-
censing trial, the maximal increase in QTcF was observed in 
weeks 1–8 [15, 30]. Notably, the odds of having the combined 
outcome (QTcF >500  ms or a change in QTcF >60  ms) was 
highest at week 15. However, incidents of QTcF >500 ms were 
detected outside this higher-risk period and in general, our data 
support the current recommendations for ECG monitoring in 
South Africa. A limitation of this study is its retrospective na-
ture and sample size. There is still a need for a prospective study 
with standardized ECG monitoring among patients receiving 
bedaquiline in routine care in the context of the 9- to 12-month 
regimen in South Africa and other settings. This would allow us 
to define patients most at risk for QTc prolongation as well as 
better define the higher-risk period, informing ECG guidelines.
In conclusion, among a cohort of patients receiving 
bedaquiline alongside clofazimine and levofloxacin for treat-
ment of DR-TB in a routine setting in South Africa, we observed 
a modest prolongation of the QTc interval, with the greatest 
QTcF increase in the first 4–6 weeks and the highest odds of 
combined outcome at week 15. We observed no arrhythmias or 
attributable deaths, adding to data suggesting that bedaquiline 
is safe under programmatic conditions.
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